Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Igf-I and longevity.

J A M J L Janssen1, S W J Lamberts

  • 1Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands. j.a.m.j.l.janssen@erasmusmc.nl

Hormone Research
|November 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disagreement in normative IGF-I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency.

Clinical endocrinology·2017
Same author

Health promotion and disease prevention can substantially reduce the total economic burden of diabetes in the Netherlands.

The Netherlands journal of medicine·2017
Same author

Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up.

International journal of obesity (2005)·2016
Same author

Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.

Endocrine-related cancer·2016
Same author

[From annual check-up to annual appraisal: personalised diabetes care].

Nederlands tijdschrift voor geneeskunde·2016
Same author

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

European journal of endocrinology·2016

Insulin and insulin-like growth factor (IGF)-I signaling pathways impact aging. While disrupting these pathways extends lifespan in animals, human studies show reduced IGF-I activity is linked to disease, not longevity.

Area of Science:

  • Gerontology
  • Endocrinology
  • Molecular Biology

Background:

  • Animal studies suggest insulin/IGF-I signaling regulates aging and longevity.
  • Disruption of these pathways extends lifespan in multiple animal models.
  • Human signaling pathways share similarities with animal models, suggesting potential for human lifespan extension.

Purpose of the Study:

  • To investigate the role of insulin/IGF-I signaling in human aging and longevity.
  • To reconcile conflicting findings between animal and human studies regarding IGF-I activity and lifespan.

Main Methods:

  • Review of existing animal and human studies on insulin/IGF-I signaling and aging.
  • Analysis of associations between IGF-I activity levels and health outcomes in humans.
  • Consideration of genetic and lifestyle factors in age-associated diseases.

Related Experiment Videos

Main Results:

  • Reduced IGF-I activity in humans is not linked to longevity.
  • Low IGF-I activity in humans correlates with increased risk of cardiovascular disease and diabetes.
  • High IGF-I activity in humans is associated with an elevated risk of cancer.

Conclusions:

  • The role of insulin/IGF-I signaling in human longevity differs from that observed in animal models.
  • Optimal IGF-I activity appears crucial for human health, with both low and high levels posing risks.
  • Individualized 'setpoints' for the insulin/growth hormone/IGF-I axis likely influence human survival and age-associated disease risk.